Selectively weakened binding of methotrexate by human dihydrofolate reductase allows rapid ex vivo selection of mammalian cells

Journal of Molecular Recognition

Volumn 24, Issue 2, 2011, Pages 188-198

  Volpato, Jordan P ^a   Mayotte, Nadine ^b   Fossati, Elena ^a   Guerrero, Vanessa ^a   Sauvageau, Guy ^b   Pelletier, Joelle N ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

ex vivo selection; hematopoietic cells; human dihydrofolate reductase; methotrexate; mutation; pemetrexed

Indexed keywords

DIHYDROFOLATE REDUCTASE; DRUG DERIVATIVE; FOLIC ACID ANTAGONIST; GLUTAMIC ACID DERIVATIVE; GUANINE; LIGAND; METHOTREXATE; MUTANT PROTEIN; PEMETREXED;

ANIMAL; ARTICLE; BONE MARROW CELL; C57BL MOUSE; CELL CULTURE; CHEMISTRY; CLONOGENIC ASSAY; CYTOLOGY; DRUG EFFECT; DRUG RESISTANCE; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; GENETIC SELECTION; GENETIC TRANSDUCTION; HUMAN; KINETICS; METABOLISM; MOUSE; TIME; VIROLOGY;

ANIMALS; BONE MARROW CELLS; CATALYTIC DOMAIN; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; DRUG RESISTANCE; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; KINETICS; LIGANDS; METHOTREXATE; MICE; MICE, INBRED C57BL; MUTANT PROTEINS; SELECTION, GENETIC; SUBSTRATE SPECIFICITY; TETRAHYDROFOLATE DEHYDROGENASE; TIME FACTORS; TRANSDUCTION, GENETIC;

BACTERIA (MICROORGANISMS); MAMMALIA; MURINAE;

EID: 79952126742     PISSN: 09523499     EISSN: 10991352     Source Type: Journal    
DOI: 10.1002/jmr.1037     Document Type: Article

References (52)

1. Allay JA, Persons DA, Galipeau J, Riberdy JM, Ashmun RA, Blakley RL, Sorrentino BP,. 1998. In vivo selection of retrovirally transduced hematopoietic stem cells. Nat. Med. 4 (10): 1136-1143. (Pubitemid 28468826)
2. Allay JA, Spencer HT, Wilkinson SL, Belt JA, Blakley RL, Sorrentino BP,. 1997. Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors. Blood 90 (9): 3546-3554. (Pubitemid 27473424)
3. Antonchuk J, Sauvageau G, Humphries RK,. 2002. HOXB4-induced expansion of adult hematopoietic stem cells ex vivo. Cell 109 (1): 39-45. (Pubitemid 34327515)
4. Ball CR, Pilz IH, Schmidt M, Fessler S, Williams DA, von Kalle C, Glimm H,. 2007. Stable differentiation and clonality of murine long-term hematopoiesis after extended reduced-intensity selection for MGMT P140K transgene expression. Blood 110 (6): 1779-1787. (Pubitemid 47443888)
5. Banerjee D, Schweitzer BI, Volkenandt M, Li MX, Waltham M, Mineishi S, Zhao SC, Bertino JR,. 1994a. Transfection with a cDNA encoding a Ser31 or Ser34 mutant human dihydrofolate reductase into Chinese hamster ovary and mouse marrow progenitor cells confers methotrexate resistance. Gene 139 (2): 269-274.
6. Banerjee D, Zhao SC, Tong Y, Steinherz J, Gritsman K, Bertino JR,. 1994b. Transfection of a nonactive site mutant murine DHFR cDNA (the tryptophan 15 mutant) into Chinese hamster ovary and mouse marrow progenitor cells imparts MTX resistance in vitro. Cancer Gene Ther. 1 (3): 181-184.
7. Blakley RL,. 1960. Crystalline Dihydropteroylglutamic Acid. Nature 188 231-232.
8. Capiaux GM, Budak-Alpdogan T, Takebe N, Mayer-Kuckuk P, Banerjee D, Maley F, Bertino JR,. 2003. Retroviral transduction of a mutant dihydrofolate reductase-thymidylate synthase fusion gene into murine marrow cells confers resistance to both methotrexate and 5-fluorouracil. Hum. Gene Ther. 14 (5): 435-446. (Pubitemid 36403536)
9. Chattopadhyay S, Moran RG, Goldman ID,. 2007. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications (Review). Mol. Cancer Ther. 6 (2): 404-417. (Pubitemid 46332443)
10. Cody V, Luft JR, Pangborn W,. 2005. Understanding the role of Leu22 variants in methotrexate resistance: comparison of wild-type and Leu22Arg variant mouse and human dihydrofolate reductase ternary crystal complexes with methotrexate and NADPH. Acta Crystallogr. D Biol. Crystallogr. 61 (Pt. 2): 147-155. (Pubitemid 43942644)
11. Das JR, Fryar EB, Epie NN, Southerland WM, Bowen D,. 2006. Raloxifene attenuation of methotrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-FU/methotrexate. Anticancer Res. 26 (3A): 1877-1883. (Pubitemid 43989445)
12. Daw NC, Billups CA, Rodriguez-Galindo C, McCarville MB, Rao BN, Cain AM, Jenkins JJ, Neel MD, Meyer WH,. 2006. Metastatic osteosarcoma. Cancer 106 (2): 403-412.
13. Emery DW, Nishino T, Murata K, Fragkos M, Stamatoyannopoulos G,. 2002. Hematopoietic stem cell gene therapy. Int. J. Hematol. 75 (3): 228-236. (Pubitemid 43014053)
14. Ercikan-Abali EA, Mineishi S, Tong Y, Nakahara S, Waltham MC, Banerjee D, Chen W, Sadelain M, Bertino JR,. 1996. Active site-directed double mutants of dihydrofolate reductase. Cancer Res. 56 (18): 4142-4145. (Pubitemid 26305006)
15. Ferraldeschi R, Thatcher N, Lorigan P,. 2007. Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial (Review). Expert Rev. Anticancer Ther. 7 (5): 635-640. (Pubitemid 46812954)
16. Flasshove M, Banerjee D, Bertino JR, Moore MA,. 1995. Increased resistance to methotrexate in human hematopoietic cells after gene transfer of the Ser31 DHFR mutant. Leukemia 9 (Suppl. 1): S34-S37.
17. Fontes AM, Davis BM, Encell LP, Lingas K, Covas DT, Zago MA, Loeb LA, Pegg AE, Gerson SL,. 2006. Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells. Mol. Cancer Ther. 5 (1): 121-128.
18. Fossati E, Volpato JP, Poulin L, Guerrero V, Dugas DA, Pelletier JN,. 2008. 2-tier bacterial and in vitro selection of active and methotrexate- resistant variants of human dihydrofolate reductase. J. Biomol. Screen. 13 (6): 504-514. (Pubitemid 351905078)
19. Frei E 3rd, Blum RH, Pitman SW, Kirkwood JM, Henderson IC, Skarin AT, Mayer RJ, Bast RC, Garnick MB, Parker LM, Canellos GP,. 1980. High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am. J. Med. 68 (3): 370-376. (Pubitemid 10130377)
20. Gangjee A, Jain HD, Phan J, Lin X, Song X, McGuire JJ, Kisliuk RL,. 2006. Dual inhibitors of thymidylate synthase and dihydrofolate reductase as antitumor agents: design, synthesis, and biological evaluation of classical and nonclassical pyrrolo[2,3-d]pyrimidine antifolates(1). J. Med. Chem. 49 (3): 1055-1065. (Pubitemid 43221653)
21. Gatlin J, Douglas J, Evans JT, Collins RH, Wendel GD, Garcia JV,. 2000. In vitro selection of lentivirus vector-transduced human CD34+ cells. Hum. Gene Ther. 11 (13): 1949-1957.
22. Gori JL, Podetz-Pedersen K, Swanson D, Karlen AD, Gunther R, Somia NV, McIvor RS,. 2007. Protection of mice from methotrexate toxicity by ex vivo transduction using lentivirus vectors expressing drug-resistant dihydrofolate reductase. J. Pharmacol. Exp. Ther. 322 (3): 989-997. (Pubitemid 47295791)
23. Gori JL, Tian X, Swanson D, Gunther R, Shultz LD, McIvor RS, Kaufman DS,. 2009. In vivo selection of human embryonic stem cell-derived cells expressing methotrexate-resistant dihydrofolate reductase. Gene Ther. 17 (2): 238-249.
24. Hashkes PJ, Laxer RM,. 2006. Update on the medical treatment of juvenile idiopathic arthritis. Curr. Rheumatol. Rep. 8 (6): 450-458. (Pubitemid 46112738)
25. Havenga MJ, Werner AB, Valerio D, van Es HH,. 1998. Methotrexate selectable retroviral vectors for Gaucher disease. Gene Ther. 5 (10): 1379-1388. (Pubitemid 28482666)
26. Jones G, Crotty M, Brooks P,. 2000. Interventions for psoriatic arthritis. Cochrane Database Syst. Rev. 3: CD000212.
27. Khersonsky O, Roodveldt C, Tawfik DS,. 2006. Enzyme promiscuity: evolutionary and mechanistic aspects (Review). Curr. Opin. Chem. Biol. 10 (5): 498-508. (Pubitemid 44375065)
28. Kopytek SJ, Dyer JC, Knapp GS, Hu JC,. 2000. Resistance to methotrexate due to AcrAB-dependent export from Escherichia coli. Antimicrob. Agents Chemother. 44 (11): 3210-3212.
29. Kramer BA, Lemckert FA, Alexander IE, Gunning PW, McCowage GB,. 2006. Characterisation of a P140K mutant O6-methylguanine-DNA-methyltransferase (MGMT)-expressing transgenic mouse line with drug-selectable bone marrow. J. Gene Med. 8 (9): 1071-1085. (Pubitemid 44480400)
30. Lewis WS, Cody V, Galitsky N, Luft JR, Pangborn W, Chunduru SK, Spencer HT, Appleman JR, Blakley RL,. 1995. Methotrexate-resistant variants of human dihydrofolate reductase with substitutions of leucine 22. Kinetics, crystallography, and potential as selectable markers. J. Biol. Chem. 270 (10): 5057-5064.
31. Li MX, Banerjee D, Zhao SC, Schweitzer BI, Mineishi S, Gilboa E, Bertino JR,. 1994. Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction. Blood 83 (11): 3403-3408. (Pubitemid 24158491)
32. Longo-Sorbello GSA, Chen BB, Budak-Alpdogan T, Bertino JR,. 2007. Role of pemetrexed in non-small cell lung cancer. Cancer Invest. 25 (1): 59-66. (Pubitemid 46423593)
33. Mahmud N, Devine SM, Weller KP, Parmar S, Sturgeon C, Nelson MC, Hewett T, Hoffman R,. 2001. The relative quiescence of hematopoietic stem cells in nonhuman primates. Blood 97 (10): 3061-3068.
34. Mamo A, Krosl J, Kroon E, Bijl J, Thompson A, Mayotte N, Girard S, Bisaillon R, Beslu N, Featherstone M, Sauvageau G,. 2006. Molecular dissection of Meis1 reveals 2 domains required for leukemia induction and a key role for Hoxa gene activation. Blood 108 (2): 622-629. (Pubitemid 44061363)
35. Mareya SM, Sorrentino BP, Blakley RL,. 1998. Protection of CCRF-CEM human lymphoid cells from antifolates by retroviral gene transfer of variants of murine dihydrofolate reductase. Cancer Gene Ther. 5 (4): 225-235. (Pubitemid 128640009)
36. Markowitz D, Goff S, Bank A,. 1988. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J. Virol. 62 (4): 1120-1124. (Pubitemid 18082924)
37. Mennes M, Stiers P, Vandenbussche E, Vercruysse G, Uyttebroeck A, De Meyer G, Van Cool SW,. 2005. Attention and information processing in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. Pediatr. Blood Cancer 44 (5): 478-486.
38. Ory DS, Neugeboren BA, Mulligan RC,. 1996. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. U. S. A. 93 (21): 11400-11406. (Pubitemid 26347133)
39. Patel M, Sleep SE, Lewis WS, Spencer HT, Mareya SM, Sorrentino BP, Blakley RL,. 1997. Comparison of the protection of cells from antifolates by transduced human dihydrofolate reductase mutants. Hum. Gene Ther. 8 (17): 2069-2077. (Pubitemid 28072577)
40. Persons DA, Allay JA, Bonifacino A, Lu T, Agricola B, Metzger ME, Donahue RE, Dunbar CE, Sorrentino BP,. 2004. Transient in vivo selection of transduced peripheral blood cells using antifolate drug selection in rhesus macaques that received transplants with hematopoietic stem cells expressing dihydrofolate reductase vectors. Blood 103 (3): 796-803. (Pubitemid 38129535)
41. Pinedo HM, Zaharko DS, Bull JM, Chabner BA,. 1976. The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides. Cancer Res. 36 (12): 4418-4424.
42. Sauerbrey A, McPherson JP, Zhao SC, Banerjee D, Bertino JR,. 1999. Expression of a novel double-mutant dihydrofolate reductase-cytidine deaminase fusion gene confers resistance to both methotrexate and cytosine arabinoside. Hum. Gene Ther. 10 (15): 2495-2504. (Pubitemid 29489723)
43. Segel IH,. 1993. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. New York: John Wiley & Sons.
44. Slamon DJ, Romond EH, Perez EA,. 2006. Advances in adjuvant therapy for breast cancer. Clin. Adv. Hematol. Oncol. 4 (Suppl 7): 4-9.
45. Sorg UR, Kleff V, Fanaei S, Schumann A, Moellmann M, Opalka B, Thomale J, Moritz T,. 2007. O6-methylguanine-DNA-methyltransferase (MGMT) gene therapy targeting haematopoietic stem cells: studies addressing safety issues. DNA Repair (Amst.) 6 (8): 1197-1209. (Pubitemid 47058402)
46. Spencer HT, Sleep SE, Rehg JE, Blakley RL, Sorrentino BP,. 1996. A gene transfer strategy for making bone marrow cells resistant to trimetrexate. Blood 87 (6): 2579-2587. (Pubitemid 26086905)
47. Strojan P, Soba E, Budihna M, Auersperg M,. 2005. Radiochemotherapy with vinblastine, methotrexate, and bleomycin in the treatment of verrucous carcinoma of the head and neck. J. Surg. Oncol. 92 (4): 278-283. (Pubitemid 41779284)
48. Volpato JP, Fossati E, Pelletier JN,. 2007. Increasing methotrexate resistance by combination of active-site mutations in human dihydrofolate reductase. J. Mol. Biol. 373 (3): 599-611. (Pubitemid 47488394)
49. Volpato JP, Yachnin BJ, Blanchet J, Guerrero V, Poulin L, Fossati E, Berghuis AM, Pelletier JN,. 2009. Multiple conformers in active site of human dihydrofolate reductase F31R/Q35E double mutant suggest structural basis for methotrexate resistance. J. Biol. Chem. 284 (30): 20079-20089.
50. Warlick CA, Diers MD, Wagner JE, McIvor RS,. 2002. In vivo selection of antifolate-resistant transgenic hematopoietic stem cells in a murine bone marrow transplant model. J. Pharmacol. Exp. Ther. 300 (1): 50-56. (Pubitemid 34028507)
51. Zhao SC, Banerjee D, Mineishi S, Bertino JR,. 1997. Post-transplant methotrexate administration leads to improved curability of mice bearing a mammary tumor transplanted with marrow transduced with a mutant human dihydrofolate reductase cDNA. Hum. Gene Ther. 8 (8): 903-909. (Pubitemid 27270152)
52. Zhao SC, Li MX, Banerjee D, Schweitzer BI, Mineishi S, Gilboa E, Bertino JR,. 1994. Long-term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double-copy vector retrovirus containing a mutant dihydrofolate reductase. Cancer Gene Ther. 1 (1): 27-33.